We often hear about new eczema treatments on the market that are promoted to us through multiple advertisement platforms. However, it’s rare to hear about the treatment drugs that fail. In this case, the MOR106 did not show promising results in the Phase 2 trial.
The decision to discontinue this drug was due to a lack of efficiency based on the severity index (EASI) score. A method researchers use to determine flare-ups and affected areas of the skin.
“We are obviously disappointed with this result of MOR106 in atopic dermatitis,” said Dr Piet Wigerinck, CSO at Galapagos. “Together with our collaboration partners, we will explore the future strategy with MOR106.”
It goes to show how complicated eczema is, from pharmaceuticals company drugs to all-natural herbal medicines. No one has quite figured it out, but we’re all determined too!